Welcome to our dedicated page for Definitive Healthcare SEC filings (Ticker: DH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Definitive Healthcare Corp. (NASDAQ: DH) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, with AI-powered tools to help interpret them. Definitive Healthcare is a Delaware corporation focused on healthcare commercial intelligence and healthcare market data and analytics, and its filings provide formal detail on its operations, governance and financial reporting.
Investors can review current reports on Form 8-K, which the company uses to disclose material events such as quarterly financial results, leadership changes and board updates. For example, Form 8-K filings reference earnings press releases for specific quarters and describe items like results of operations, director resignations, committee appointments and executive leadership changes.
In addition to 8-Ks, users can access Definitive Healthcare’s annual reports on Form 10-K and quarterly reports on Form 10-Q, which contain audited and interim financial statements, management’s discussion and analysis, risk factors, and segment and non-GAAP metric disclosures. These documents expand on metrics highlighted in earnings releases, including Adjusted EBITDA, Adjusted Gross Profit, Adjusted Operating Income, Adjusted Net Income and Unlevered Free Cash Flow.
Stock Titan’s platform enhances these filings with AI-generated summaries that explain key sections, highlight important changes and clarify complex accounting or non-GAAP reconciliations. Real-time updates from EDGAR help ensure that new filings, including any Form 4 insider transaction reports or proxy statements related to executive compensation and governance, appear promptly.
For users researching DH stock, this page offers a structured way to read, compare and understand Definitive Healthcare’s regulatory history, financial reporting practices and corporate actions without manually parsing every line of each SEC document.
Definitive Healthcare Corp. provides a SaaS healthcare data and analytics platform that supports commercial decisions across life sciences, providers and diversified healthcare customers. It serves approximately 2,330 customers and derives 96% of its revenue from subscriptions.
For the year ended December 31, 2025, the company reported a net loss of $199.3 million, an improvement from a net loss of $591.4 million in 2024. As of December 31, 2025, its workforce totaled 686 employees across the U.S., Europe and India. The report emphasizes intense competition, reliance on third‑party data, evolving privacy and security rules, macroeconomic pressures on customer spending, and execution risks around AI, innovation, acquisitions and restructuring.
Definitive Healthcare reported mixed 2025 results with improving profitability metrics but lower revenue. Q4 2025 revenue was $61.5 million, down 1% from $62.3 million in Q4 2024, while Adjusted EBITDA rose slightly to $18.0 million, or 29% of revenue, from $17.5 million and 28% a year earlier. Q4 net loss narrowed sharply to $17.1 million, including $19.5 million of goodwill impairment, compared with an $84.7 million loss including $97.1 million of impairment in Q4 2024.
For full year 2025, revenue was $241.5 million versus $252.2 million in 2024. Net loss was $199.3 million, including $196.1 million in goodwill impairment, improving from a $591.4 million loss with $688.9 million of impairment in 2024. Adjusted EBITDA was $70.4 million, or 29% of revenue, down from $79.1 million and a 31% margin. Operating cash flow reached $53.8 million and Unlevered Free Cash Flow was $54.9 million.
For 2026, the company guides revenue to $220.0–$226.0 million, Adjusted EBITDA to $53.0–$58.0 million with a 24–26% margin, and Adjusted Net Income to $21.0–$26.0 million, or $0.14–$0.17 per diluted share.
Goldman Sachs Group and Goldman Sachs & Co. LLC report beneficial ownership of 5,935,933 shares of Definitive Healthcare Corp Class A common stock, representing 5.7% of the class as of 12/31/2025.
They report shared voting power over 5,934,807 shares and shared dispositive power over 5,935,933 shares. The firms state the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Definitive Healthcare.
Definitive Healthcare Corp. Executive Chairman Jason Ronald Krantz reported a tax-related share withholding on February 1, 2026. The issuer withheld 44,545 shares of Class A Common Stock at $2.32 per share to cover tax obligations linked to vesting of previously reported restricted stock units.
After this transaction, Krantz beneficially owned 1,016,039 Class A shares directly and 450,000 shares indirectly through DH Holdings (formerly the Jason R. Krantz 2009 Trust), where he is the beneficiary.
Definitive Healthcare Corp. reported a routine insider tax withholding transaction by its Chief Financial Officer. On 02/01/2026, CFO Casey Heller had 1,469 shares of Class A common stock withheld by the company at $2.32 per share to cover tax obligations tied to vesting restricted stock units. After this withholding, Heller beneficially owned 1,274,021 Class A common shares directly.
Definitive Healthcare Corp. reported that its Chief Financial Officer, Casey Heller, received an equity grant of 195,313 Class A common shares in the form of restricted stock units on January 5, 2026. These RSUs carry a grant price of $0 per share, reflecting a compensation award rather than an open-market purchase.
Each RSU represents the right to receive one share of Class A common stock, with 50% vesting on January 1, 2027. The remaining half vests in equal quarterly installments over the following 12 months, conditioned on Heller’s continued service with the company. After this grant, Heller directly beneficially owns 1,275,490 shares of Class A common stock.
Definitive Healthcare Corp. reported Q3 2025 revenue of $60.0 million versus $62.7 million a year ago, with gross profit of $46.0 million. Loss from operations was $8.7 million. Net loss attributable to Definitive Healthcare narrowed to $14.8 million from $130.9 million in Q3 2024, which included a large impairment.
Year to date, revenue was $180.0 million and operating cash flow was $51.1 million. The company reduced its 2021 Term Loan principal to $168.4 million and had no borrowings on its $50.0 million revolver, with $49.7 million available after a standby letter of credit. Total assets were $755.5 million, including goodwill of $216.8 million following a $176.5 million non‑cash goodwill impairment recorded in Q1 2025. Deferred revenue was $92.0 million, and remaining performance obligations totaled $247.3 million. Class A shares outstanding were 103,011,649 as of September 30, 2025.
Definitive Healthcare Corp. (DH) reported a filing action. The company furnished an Item 2.02 Form 8‑K to announce it issued a press release with financial results for the third quarter ended September 30, 2025. The press release is included as Exhibit 99.1. The company states the information in Item 2.02 and Exhibit 99.1 is being furnished, not filed, and is not subject to Section 18 liabilities nor incorporated by reference into other filings.
Definitive Healthcare Corp. (DH) disclosed an insider transaction by its Chief Financial Officer on a Form 4. On 11/01/2025, the CFO had 1,244 shares of Class A common stock withheld at $2.77 per share under transaction code F, which indicates shares were withheld to cover taxes on vested restricted stock units. Following this administrative withholding, the officer beneficially owns 1,080,177 shares directly. The footnote confirms the activity was tied to the vesting and settlement of previously reported RSUs.
Definitive Healthcare (DH) reported an insider transaction by its Executive Chairman and Director. On 11/01/2025, 18,796 shares of Class A common stock were withheld by the company at $2.77 per share to cover tax obligations upon the vesting and settlement of previously reported RSUs. Following this administrative transaction, the reporting person beneficially owns 1,060,584 shares directly and 450,000 shares indirectly through DH Holdings (f/k/a Jason R. Krantz 2009 Trust), of which he is the beneficiary.